Scholarlink

Background <p>Programmed death-ligand 1 (PD-L1) has traditionally been regarded as a membrane-bound immune checkpoint ligand that suppresses antitumor T-cell activity through PD-1 engagement. Although this framework remains fundamental, it is no longer sufficient to capture the full biologic and clinical complexity of PD-L1 in cancer. Accumulating evidence indicates that PD-L1 is not a static surface marker, but a dynamically regulated molecular hub positioned at the intersection of inflammatory signaling, tumor-cell adaptation, and immune escape.</p> Main body <p>Within the tumor microenvironment, inflammatory cues including interferons, TNF-<InlineEquation ID="IEq1"><EquationSource Format="TEX">\(\alpha \)</EquationSource></InlineEquation>, IL-6, Toll-like receptor signaling, hypoxia, and therapy-induced stress regulate PD-L1 through transcriptional, post-transcriptional, and post-translational mechanisms. These inputs do not merely increase PD-L1 abundance. They shape PD-L1 protein fate through glycosylation, ubiquitination, palmitoylation, endocytic trafficking, recycling, and degradation, thereby determining membrane abundance, localization, and activity. Beyond canonical PD-1 ligation, PD-L1 can also exert tumor-intrinsic effects, mediate exosomal immunosuppressive communication, and adopt context-dependent nuclear functions linked to stress adaptation and treatment resistance. In turn, PD-L1 participates in self-reinforcing circuits involving exhausted T cells, myeloid suppressor populations, stromal signaling, additional checkpoint-sensitive immune compartments, and therapy-driven adaptive resistance. We distinguish validated from emerging PD-L1 states across experimental models and human tumors.</p> Conclusion <p>A framework linking inflammatory input, PD-L1 protein fate, functional output, and feedback provides an integrated view of PD-L1 biology in cancer. Translationally, this framework argues for moving beyond single-point PD-L1 testing toward integrated assessment of inflammatory context, spatial organization, and dynamic PD-L1 states, while supporting mechanism-guided combination strategies targeting the PD-L1 axis.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Inflammatory regulation of PD-L1 protein fate in the tumor microenvironment shapes immune escape and therapeutic targeting

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月9日

查看全文
  • Kuan Liang,
  • Ziang Jia,
  • Haiwen Lu,
  • Qianqian Wang,
  • Haihui Huang,
  • Ziling Yan,
  • Yukun Wang,
  • Xia Liu

摘要

Background

Programmed death-ligand 1 (PD-L1) has traditionally been regarded as a membrane-bound immune checkpoint ligand that suppresses antitumor T-cell activity through PD-1 engagement. Although this framework remains fundamental, it is no longer sufficient to capture the full biologic and clinical complexity of PD-L1 in cancer. Accumulating evidence indicates that PD-L1 is not a static surface marker, but a dynamically regulated molecular hub positioned at the intersection of inflammatory signaling, tumor-cell adaptation, and immune escape.

Main body

Within the tumor microenvironment, inflammatory cues including interferons, TNF-\(\alpha \), IL-6, Toll-like receptor signaling, hypoxia, and therapy-induced stress regulate PD-L1 through transcriptional, post-transcriptional, and post-translational mechanisms. These inputs do not merely increase PD-L1 abundance. They shape PD-L1 protein fate through glycosylation, ubiquitination, palmitoylation, endocytic trafficking, recycling, and degradation, thereby determining membrane abundance, localization, and activity. Beyond canonical PD-1 ligation, PD-L1 can also exert tumor-intrinsic effects, mediate exosomal immunosuppressive communication, and adopt context-dependent nuclear functions linked to stress adaptation and treatment resistance. In turn, PD-L1 participates in self-reinforcing circuits involving exhausted T cells, myeloid suppressor populations, stromal signaling, additional checkpoint-sensitive immune compartments, and therapy-driven adaptive resistance. We distinguish validated from emerging PD-L1 states across experimental models and human tumors.

Conclusion

A framework linking inflammatory input, PD-L1 protein fate, functional output, and feedback provides an integrated view of PD-L1 biology in cancer. Translationally, this framework argues for moving beyond single-point PD-L1 testing toward integrated assessment of inflammatory context, spatial organization, and dynamic PD-L1 states, while supporting mechanism-guided combination strategies targeting the PD-L1 axis.